GTX-104 not checked

Grace Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Main trialPhase 3
“The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.”In the company’s words, NCT05995405 on ClinicalTrials.gov
Copy of
Nimotop (Bayer Pharms)Tested side by side with the original in NCT05995405

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2024 Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Phase 1Completed 17 Feb 2022 Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GTX-104

Following is part of Solo: you see every change to GTX-104 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in